Skip to main content

Table 2 Description of symptoms of CHIK IgG-positive patients who presented manifestations of acute CHIK infection (n = 32)

From: Treatment with biological therapy is associated with faster recovery and lower frequency of treatment switch among rheumatic patients with Chikungunya fever

 

bDMARD (n = 14)

csDMARD-only (n = 18)

p-value*

Acute phase symptoms

Fever

13 (92.9)

18 (100.0)

0.437

Rash

7 (50.0)

9 (50.0)

1.000

Morning Stiffness

10 (71.4)

13 (72.2)

1.000

Fatigue

7 (50.0)

15 (83.3)

0.062

Itching

5 (35.7)

8 (44.4)

0.618

Paraesthesia

4 (28.6)

9 (50.0)

0.221

Lower limb edema

6 (42.9)

11 (61.1)

0.305

Myalgia

7 (50.0)

14 (77.8)

0.142

Arthritis

12 (85.7)

16 (88.9)

1.000

Headache

9 (64.3)

16 (88.9)

0.195

Gastrointestinal symptoms

3 (21.4)

06 (33.3)

0.694

Respiratory symptoms

3 (21.4)

04 (22.2)

1.000

Worsening of articular symptoms after the acute phase

None

0 (0.0)

0 (0.0)

0.283

Mild

1 (7.1)

0 (0.0)

 

Moderate

2 (14.3)

3 (16.7)

 

Severe

8 (57.1)

7 (38.9)

 

Very severe

3 (21.4)

8 (44.4)

 

Persistence of articular symptoms for > 3 months

2 (14.2)

10 (55.6)

0.017

Treatment switch

3 (21.4)

11 (61.1)

0.025

Change in corticosteroid dose

4 (28.6)

8 (44.4)

0.357

  1. The definition for significance of bold is p < 0.05
  2. *Pearson Chi-Square test or Fisher’s exact test
  3. CHIK Chikungunya fever, TNF Tumor necrosis factor, csDMARD Conventional synthetic disease-modifying antirheumatic drugs, bDMARD Biological disease-modifying antirheumatic drugs